{"id":"gardasil-9-rescue-dose","safety":{"commonSideEffects":[{"rate":"48-61%","effect":"Injection site pain"},{"rate":"25-35%","effect":"Injection site swelling"},{"rate":"24-34%","effect":"Injection site erythema"},{"rate":"11-16%","effect":"Headache"},{"rate":"1-3%","effect":"Fever"},{"rate":"4-6%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL6068359","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gardasil 9 contains virus-like particles (VLPs) derived from the major capsid protein of nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58). When administered, these VLPs trigger a humoral immune response that generates neutralizing antibodies against these HPV types, preventing viral infection of epithelial cells and reducing the risk of HPV-related malignancies and genital warts. A 'rescue dose' refers to an additional dose administered to individuals who may have incomplete prior vaccination series or suboptimal immune response.","oneSentence":"Gardasil 9 is a recombinant vaccine that stimulates the immune system to produce antibodies against nine types of human papillomavirus (HPV) to prevent infection and associated cancers.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:05.089Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of cervical cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58"},{"name":"Prevention of anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58"},{"name":"Prevention of genital warts caused by HPV types 6, 11"},{"name":"Prevention of oropharyngeal and other head and neck cancers caused by HPV"}]},"trialDetails":[{"nctId":"NCT04206813","phase":"PHASE4","title":"An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Medical Center","startDate":"2020-12-01","conditions":"HPV Infection","enrollment":352}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Human Papillomavirus 9-valent Vaccine, Recombinant"],"phase":"marketed","status":"active","brandName":"Gardasil 9 rescue dose","genericName":"Gardasil 9 rescue dose","companyName":"Boston Medical Center","companyId":"boston-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gardasil 9 is a recombinant vaccine that stimulates the immune system to produce antibodies against nine types of human papillomavirus (HPV) to prevent infection and associated cancers. Used for Prevention of cervical cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58, Prevention of anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58, Prevention of genital warts caused by HPV types 6, 11.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}